Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
18 Results for "
ADPKD
" in MedChemExpress (MCE) Product Catalog:
Products (18)
18 Results for "ADPKD" in MCE Product Catalog:
2
Target:
Research Areas:
RGLS4326 (RG4326) is a first-in-class, short oligonucleotide inhibitor of microRNA-17 (miR-17). RGLS4326 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 inhibits miR-17 function in HeLa cells with an EC50 value of 28.3 nM .
2
2 Cited Publications
Target:
Research Areas:
MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM .
2
RGLS4326 sodium is a first-in-class, short oligonucleotide inhibitor of microRNA-17 (miR-17). RGLS4326 sodium can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 sodium inhibits miR-17 function in HeLa cells with an EC50 value of 28.3 nM .
1
1 Cited Publications
Target:
Research Areas:
GFB-12811 is a high selective CDK5 inhibitor with an IC50 of 2.3 nM .
Cat. No.: HY-150364A
CAS No.: 2921918-19-4
Synonyms: RGLS8429 sodium; RG1015 sodium
Target:
Research Areas:
Farabursen sodium (RGLS8429 sodium; RG1015 sodium) is a miR-17 inhibitor. Farabursen sodium inhibits the function of the miR-17 family, relieves the inhibitory effect on miR-17 target genes including PKD1 and PKD2, and increases the level of PC1/2. Farabursen sodium slows the growth of renal cysts, reduces the ratio of kidney weight to body weight, and decreases the cyst index and proliferation index. Farabursen sodium is applicable to research related to autosomal dominant polycystic kidney disease .
Cat. No.: HY-150364
CAS No.: 2953012-32-1
Synonyms: RGLS8429; RG1015
Target:
Research Areas:
Farabursen (RGLS8429; RG1015) is a blood-brain barrier-permeable miR-17 inhibitor. Farabursen derepresses Pkd1 and Pkd2, the target genes of miR-17, increases the levels of PC1 and PC2, and reduces cyst growth. Farabursen decreases renal cyst growth, kidney weight-to-body weight ratio, cyst index, proliferation index, and blood urea nitrogen levels in mouse models. Farabursen is applicable to research related to autosomal dominant polycystic kidney disease .
CDK5-IN-3 (compound 11) is a potent CDK5 inhibitor, with IC50s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA, respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD) .
Cat. No.: HY-176255
Target:
Research Areas:
TBK1 degrader-4 (Compound 30) is a molecular glue degrader targeting TBK1. TBK1 degrader-4 effectively inhibits cyst growth, alleviates inflammation, and reduces the levels of pro-inflammatory factors such as Ccl2, IFNβ, and IL-6. TBK1 degrader-4 is promising for research of autosomal dominant polycystic kidney disease (ADPKD) .
Cat. No.: HY-177493
CAS No.: 3086695-73-7
Target:
Research Areas:
SSTR3 Agonist-1 (Compound EX 38) is an orally active SSTR3 agonist, with an EC50 of 0.14 nM. SSTR3 Agonist-1 reduces the kidney cystic index. SSTR3 Agonist-1 can be used in the research of autosomal dominant polycystic kidney disease .
Cat. No.: HY-151878
CAS No.: 3034210-97-1
Research Areas:
CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC50 value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research .
Cat. No.: HY-146272
CAS No.: 2648650-50-2
Target:
Research Areas:
Vasopressin V2 receptor antagonist 1 is a vasopressin V2 receptor (V2R) antagonist with a Ki value of 3.8 nM. Vasopressin V2 receptor antagonist 1 inhibits renal cyst formation in embryonic renal cyst models and mouse models. Vasopressin V2 receptor antagonist 1 can be used in research related to autosomal dominant polycystic kidney disease .
Cat. No.: HY-177493A
Target:
Research Areas:
SSTR3 agonist-1 TFA is a potent, orally active, and selective SSTR3 agnoist (EC50 =0.14 nM). SSTR3 agonist-1 TFA binds to SSTR3 receptor to inhibit cAMP activity. SSTR3 agonist-1 TFA decreases kidney weight and kidney cystic index (KCI) in a mouse model of autosomal dominant polycystic kidney disease (ADPKD). SSTR3 agonist-1 TFA can be used for ADPKD research .
Cat. No.: HY-W702907
CAS No.: 1346599-56-1
Target:
Research Areas:
DM-4103 is a major metabolite of Tolvaptan (HY-17000) that is metabolized primarily by the CYP3A4 enzyme in the liver. DM-4103 inhibits the ability of human liver transporters NTCP, BSEP, MRP2, MRP3, MRP4 (IC50 values are 16.3, 4.15, 51.0, 44.6, 4.26 μM, respectively) and bile acid transport in SCHH cells. DM-4103 can be used in the study of autosomal dominant polycystic kidney disease (ADPKD) .
Cat. No.: HY-161524
CAS No.: 3037978-19-8
HDAC6-IN-43 (compound 26) is a potent HDAC inhibitor. HDAC6-IN-43 effectively inhibits several HDACs, notably HDAC1, HDAC2, and HDAC6 (IC50 < 150 nM), displaying a particularly high sensitivity towards HDAC6 (IC50 = 11 nM). HDAC6-IN-43 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD) .
Cat. No.: HY-117051
CAS No.: 1046490-67-8
STA-2842 is an inhibitor of heat shock protein HSP90 with potential to inhibit autosomal dominant polycystic kidney disease (ADPKD). ADPKD is caused by inherited mutations in the PKD1 or PKD2 genes that abnormally activate multiple signaling proteins and pathways that regulate cell proliferation. STA-2842 can significantly reduce initial renal cyst formation and kidney growth in mice, and slow disease progression in mice with existing cysts.
Cat. No.: HY-W702908
CAS No.: 1346599-75-4
Target:
Research Areas:
DM-4107 is a major metabolite of Tolvaptan (HY-17000) that is metabolized primarily by the CYP3A4 enzyme in the liver. DM-4107 inhibits the ability of human liver transporters NTCP, BSEP, MRP3, MRP4 (IC50 values are 95.6, 119, 61.2, 37.9 μM, respectively) and bile acid transport in SCHH cells. DM-4107 can be used in the study of autosomal dominant polycystic kidney disease (ADPKD) .
Cat. No.: HY-182904
CAS No.: 3082707-76-1
Research Areas:
GV-001 is a selective and orally active HDAC6 inhibitor with an IC50 of 1.18 nM against HDAC6. GV-001 selectively enhances α-tubulin acetylation, reduces sIL-6 and Collagen I levels, suppresses renal cyst growth, and upregulates PC1 expression. GV-001 can be used for the study of autosomal dominant polycystic kidney disease (ADPKD) .
Cat. No.: HY-180142
Target:
Research Areas:
XYDC2050 (Compound 29) is a selective vasopressin V2 receptor (V2R) antagonist with an IC50 of 27 nM and a Ki of 2.8 nM. XYDC2050 shows a Ki of 420.7 nM (SI = 162 fold) for V1R. XYDC2050 can inhibit Vasopressin (HY-B1811)-induced intracellular cyclic adenosine monophosphate (cAMP) accumulation with an IC50 of 12 nM. XYDC2050 can inhibit the growth of renal cysts, reduce the ratio of kidney weight to body weight and decrease the area of cysts and the cystic index. XYDC2050 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD) .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
